| scholarly article | Q13442814 |
| P50 | author | Mika K Kaneko | Q90664257 |
| Yukinari Kato | Q42292347 | ||
| P2093 | author name string | Satoshi Ogasawara | |
| Takuro Nakamura | |||
| Michiaki Takagi | |||
| Hiroyoshi Suzuki | |||
| Shinji Abe | |||
| Yasuhiko Nishioka | |||
| Hiroyuki Harada | |||
| Yuki Fujii | |||
| Ryusuke Honma | |||
| P2860 | cites work | Overexpression of podoplanin in oral cancer and its association with poor clinical outcome | Q79805143 |
| Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors | Q80551972 | ||
| Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma | Q81436908 | ||
| Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin | Q85409383 | ||
| Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus | Q85475870 | ||
| PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin | Q87199512 | ||
| LpMab-19 Recognizes Sialylated O-Glycan on Thr76 of Human Podoplanin | Q88209080 | ||
| Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors | Q24675750 | ||
| A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin | Q27696295 | ||
| Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state | Q27704010 | ||
| Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors | Q28206434 | ||
| The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis | Q28221740 | ||
| Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma | Q28241842 | ||
| Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells | Q28269958 | ||
| Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas | Q28290560 | ||
| Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression | Q28305905 | ||
| Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain | Q28576484 | ||
| Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. | Q30032296 | ||
| Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. | Q30032661 | ||
| Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. | Q31133789 | ||
| A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin | Q33985502 | ||
| Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas | Q34160649 | ||
| Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium | Q34502407 | ||
| Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis | Q34522088 | ||
| LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin | Q35975006 | ||
| The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. | Q36546538 | ||
| Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours | Q36617968 | ||
| Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors | Q37259430 | ||
| Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. | Q37562162 | ||
| Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin. | Q38825833 | ||
| Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin | Q38825838 | ||
| Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin | Q38905443 | ||
| Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. | Q39311213 | ||
| Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma | Q39498357 | ||
| Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression | Q39537008 | ||
| Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification | Q39951477 | ||
| Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells | Q40022043 | ||
| Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. | Q40065992 | ||
| Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. | Q40399669 | ||
| Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin. | Q40769432 | ||
| Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin. | Q42002432 | ||
| Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. | Q42826024 | ||
| A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. | Q43934606 | ||
| IgG3 is the major source of cryoglobulins in mice. | Q47897852 | ||
| Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. | Q48501703 | ||
| PMab-44 Detects Bovine Podoplanin in Immunohistochemistry. | Q51717799 | ||
| Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. | Q51766105 | ||
| Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. | Q51787002 | ||
| Podoplanin expressing cancer-associated fibroblasts in oral cancer. | Q53027845 | ||
| Anti-podoplanin Monoclonal Antibody LpMab-7 Detects Metastatic Lesions of Osteosarcoma. | Q53462478 | ||
| Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin. | Q53762694 | ||
| Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. | Q54333727 | ||
| P4510 | describes a project that uses | PDIS-6 | Q54946849 |
| PDIS-9 | Q54946850 | ||
| PDIS-1 | Q54946843 | ||
| PDIS-12 | Q54946844 | ||
| PDIS-14 | Q54946845 | ||
| PDIS-2 | Q54946846 | ||
| PDIS-22 | Q54946847 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CRISPR | Q412563 |
| monoclonal antibody | Q422248 | ||
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| cell line | Q21014462 | ||
| P304 | page(s) | 382-396 | |
| P577 | publication date | 2017-01-19 | |
| P1433 | published in | Cancer Medicine | Q27724564 |
| P1476 | title | Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN. | |
| P478 | volume | 6 |
| Q127382607 | LN229/hPDPN |
| Q127382632 | LpMab-21 |
| Q54946843 | PDIS-1 |
| Q54946844 | PDIS-12 |
| Q54946845 | PDIS-14 |
| Q54946846 | PDIS-2 |
| Q54946847 | PDIS-22 |
| Q54946849 | PDIS-6 |
| Q54946850 | PDIS-9 |
| Q42292310 | Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity |
| Q50351148 | C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets |
| Q50162292 | Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry |
| Q89219422 | Disodium Cromolyn and Anti-podoplanin Antibodies Strongly Inhibit Growth of BHK 21/C13-derived Fibrosarcoma in a Chick Embryo Chorioallantoic Membrane Model |
| Q47803240 | Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry. |
| Q52842322 | Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity. |
| Q53167213 | H2Mab-77 is a Sensitive and Specific Anti-HER2 Monoclonal Antibody Against Breast Cancer. |
| Q48367537 | Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis. |
Search more.